Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ATLAS PHARMS LLC","sponsor":"TME Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxxon Announces Manufacturing of NOX-A12 Drug Substance and Issuance of Convertible Bonds Under Financing Agreement With Atlas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by ATLAS PHARMS LLC

    Menu

    ATLAS PHARMS LLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ATLAS PHARMS LLC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Noxxon Announces Manufacturing of NOX-A12 Drug Substance and Issuance of Convertible Bonds Under Financing Agreement With Atlas

              Details:

              As NOXXON advances its pipeline with upcoming start of clinical trials this additional liquidity will focus on manufacturing of NOX-A12 clinical trial supply in anticipation of upcoming clinical trials.

              Lead Product(s): Olaptesed Pegol,Pembrolizumab,Irinotecan Hydrochloride

              Therapeutic Area: Oncology Product Name: NOX-A12

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: TME Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing June 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY